-
-
-
-
-
-
-
BioCryst names David Jenkins as chief scientific officer
-
-
-
-
-
-
-
BioCryst licenses navenibart to Neopharmed Gentili for European market
-
-
-
-
-
-
-
Evercore ISI Resumes BioCryst Pharma (BCRX) at Outperform, Adds to Core SMID list
-
-
-
-
-
-
-
TD Cowen Reiterates Buy Rating on BioCryst Pharma (BCRX)
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on BioCryst Pharma (BCRX)
-
-
-
-
-
-
-
BioCryst Pharma (BCRX) Halted, News Pending
-
-
-
-
-
-
-
BioCryst Pharma (BCRX) Announces Sale of European ORLADEYO Business to Neopharmed Gentili for up to $264 Million
-
479,043 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


